8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
2010 / Randomized, double-blind, placebo-controlled dose-ranging trial
In a dose-ranging study, 255 adult inpatients starting antibiotics were randomized to two probiotic capsules daily (Pro-2, 100 billion c.f.u.), one probiotic plus one placebo capsule daily (Pro-1, 50 billion c.f.u.), or two placebo capsules daily. AAD incidence was 15.5% in Pro-2, 28.2% in Pro-1, and 44.1% in the placebo group; in those who developed AAD, symptom duration was 2.8 days (Pro-2), 4.1 days (Pro-1), and 6.4 days (placebo). CDAD incidence was also reduced: 1.2% in Pro-2, 9.4% in Pro-1, and 23.8% in placebo. Gastrointestinal symptoms were less frequent in the probiotic groups compared to placebo and lower in Pro-2 than in Pro-1.
Gao XW, Mubasher M, Fang CY, et al. Am J Gastroenterol, 2010. PMID 20145608
2010 / Uncontrolled before-and-after trial
Researchers screened 540 patients reporting clinical allergy symptoms using skin prick tests for food allergens plus Ani s1 (an A. simplex allergen). A total of 170 subjects had positive skin prick tests, and 87 (51.2%) were positive for Ani s1. Intestinal permeability was measured at baseline and after 6 months of a raw fish-free diet. Increased intestinal permeability observed in sensitized subjects with worse clinical symptoms receded after the 6-month elimination of raw seafood.
Polimeno L, Loiacono M, Pesetti B, et al. Foodborne Pathog Dis, 2010. PMID 20367330
2010 / Open-label crossover trial
An open-label crossover trial tested cow's milk and rice milk phases in 69 children meeting Rome III criteria for chronic constipation. Overall, 27 of 69 children (39%) developed constipation during milk challenge and improved during milk-free phases, with weekly bowel movements increasing significantly compared with non-responders (2.8 to 7.7 vs 2.6 to 2.7, P < 0.001). Immunologic measures, including total and milk-specific immunoglobulin E, did not differ significantly between responders and non-responders.
Irastorza I, Ibañez B, Delgado-Sanzonetti L, et al. J Pediatr Gastroenterol Nutr, 2010. PMID 20453672
2010 / Randomized controlled trial
A randomized trial evaluated daily oral supplementation with 1,200 IU vitamin D3 versus placebo over 12 months in 94 patients with Crohn's disease in remission. Vitamin D3 elevated mean serum 25OHD from 69 nmol/L to 96 nmol/L after 3 months (P < 0.001). Clinical relapse occurred in 13% (6/46) of the vitamin D3 group versus 29% (14/48) of the placebo group, which did not reach statistical significance (P = 0.06).
Jørgensen SP, Agnholt J, Glerup H, et al. Aliment Pharmacol Ther, 2010. PMID 20491740
2010 / Crossover intervention trial
Nineteen subjects followed a high-total antioxidant capacity (HT) diet and a low-TAC (LT) diet for 2 weeks in a crossover design, matched for energy, macronutrients, total fiber, and alcohol. Intake of TAC, vitamins E and C, and phenolics increased during the HT diet. The HT diet resulted in greater 48 h stool output (324 [SD 38] g in HT vs. 218 [SD 22] g in LT), along with higher TAC and total phenolic concentrations in fecal water. No significant variations were seen in fecal moisture, pH, ammonia, Lactobacillus and Bifidobacterium counts, or genotoxicity.
Bianchi MA, Scazzina F, Del Rio D, et al. Br J Nutr, 2010. PMID 20579404
2010 / Randomized crossover trial
In a randomized crossover trial, 15 healthy young adults consumed 8 different cereal-based evening test meals containing 50 g available starch on separate nights. Evening meals with high-amylose or high-beta-glucan barley kernels produced higher morning plasma butyrate levels than white wheat bread (P < 0.05). Following a standard breakfast, postprandial glucose response was inversely associated with morning plasma butyrate (r = -0.26; P < 0.01) and acetate (r = -0.20; P < 0.05).
Nilsson AC, Östman EM, Knudsen KE, et al. J Nutr, 2010. PMID 20810606
2010 / Controlled dietary intervention trial
This 6-week, three-phase study assessed the effect of eating two Hayward green kiwifruits daily for 4 weeks compared to two placebo capsules daily in patients with IBS/C (41 kiwifruit, 13 placebo) along with 16 healthy adults consuming kiwifruit. After the 4-week intervention, weekly defecation frequency significantly increased (p<0.05) and colon transit time significantly decreased (p=0.026) in IBS/C participants who consumed kiwifruit. The findings suggest that consuming kiwifruit for 4 weeks shortens colon transit time and improves bowel function in adults with IBS/C.
Chang CC, Lin YT, Lu YT, et al. Asia Pac J Clin Nutr, 2010. PMID 21147704
2010 / Randomized crossover trial
Twelve healthy adults consumed control, chickpea-supplemented (200 g/day), or raffinose-supplemented (5 g/day) diets for three weeks each in a randomized crossover trial. Both chickpea and raffinose diets increased the abundance of Faecalibacterium prausnitzii compared to control. No significant differences occurred in fecal short-chain fatty acid concentrations, while fewer subjects carried Clostridium histolyticum–lituseburense group bacteria on the chickpea diet.
Fernando WM, Hill JE, Zello GA, et al. Benef Microbes, 2010. PMID 21831757
2010 / Experimental physiological study
Six healthy volunteers were evaluated in three defecation positions: sitting, sitting with hips flexed at 60°, and squatting with hips flexed at 22.5°. Basal abdominal pressure before defecation during squatting (26 cmH2O) was significantly lower than during normal sitting (P < 0.01). The rectoanal angle during defecation while squatting (126°) was significantly larger than during normal sitting (100°, P < 0.05) and hip-flex sitting (99°, P < 0.01). Differences in abdominal pressure increase (strain) between positions did not reach statistical significance.
Sakakibara R, Tsunoyama K, Hosoi H, et al. Low Urin Tract Symptoms, 2010. PMID 26676214
2009 / Randomized controlled trial
Ninety-one overweight or obese adults followed an energy-restricted low-carbohydrate or high-carbohydrate diet for 8 weeks. Compared with the high-carbohydrate plan, the low-carbohydrate diet significantly reduced fecal output, defecation frequency, butyrate concentrations (-3.9 vs. -0.5 mmol/l), total short-chain fatty acids (-15.8 vs. 1.4 mmol/l), and bifidobacteria counts. Both diets showed similar self-reported gastrointestinal tolerance and adverse symptom rates.
Brinkworth GD, Noakes M, Clifton PM, et al. Br J Nutr, 2009. PMID 19224658
2009 / Randomized, double-blind, placebo-controlled pilot study
In this pilot study, 39 chronic fatigue syndrome patients were randomized to receive either 24 billion colony forming units of Lactobacillus casei strain Shirota (LcS) or a placebo daily for two months. Patients provided stool samples and completed the Beck Depression and Beck Anxiety Inventories before and after treatment. There was a significant rise in both Lactobacillus and Bifidobacteria in the LcS group, along with a significant decrease in anxiety symptoms compared to controls (p = 0.01).
Rao AV, Bested AC, Beaulne TM, et al. Gut Pathog, 2009. PMID 19338686
2009 / Prospective comparative study with matched groups
A prospective study followed 37 inactive Crohn's disease patients in two matched groups receiving either active or plain vitamin D. At six weeks, the active form was linked to lower disease activity index values (69.44 vs 57.0) and C-reactive protein (15.8 vs 7.81 mmol/L, P < 0.05). Markers of bone turnover also decreased and osteoprotegerin rose with the active form. These biochemical changes were stronger at three months but disappeared by month 12.
Miheller P, Muzes G, Hritz I, et al. Inflamm Bowel Dis, 2009. PMID 19408329
2009 / Double-blind, placebo-controlled crossover trial
A double-blind, placebo-controlled crossover trial evaluated the consumption of 250 ml mare's milk or placebo for 16 weeks in 23 patients with atopic dermatitis. The mean SCORAD value decreased from 30.1 to 25.3 after 12 weeks (P<0.05) and to 26.7 after 16 weeks (P<0.1) during the mare's milk period. In a subgroup of 7 patients, the SCORAD index and pruritus decreased by 30% (P<0.01), accompanied by an increase in faecal bifidobacteria from 4.6% to 11.9% of eubacteria (P<0.05). Immunological parameters remained unchanged, with the exception of C-reactive protein.
NANO counterpoint →
Foekel C, Schubert R, Kaatz M, et al. Int J Food Sci Nutr, 2009. PMID 19462320
2009 / Randomized, double-blind, parallel, placebo-controlled trial
Ten healthy adults were randomly assigned to receive either 16 g prebiotics/d or 16 g dextrin maltose/d for 2 weeks. Prebiotic treatment increased breath-hydrogen excretion approximately 3-fold, lowered hunger rates, and increased plasma glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) concentrations while decreasing postprandial glucose responses. Areas under the curve for postprandial GLP-1 and breath-hydrogen were significantly correlated (r = 0.85, P = 0.007), and glucose response was inversely correlated with breath-hydrogen AUC (r = -0.73, P = 0.02).
Cani PD, Lecourt E, Dewulf EM, et al. Am J Clin Nutr, 2009. PMID 19776140
2008 / Randomized controlled trial
In a double-blind trial, 296 patients with predicted severe acute pancreatitis received a multispecies probiotic preparation or placebo twice daily for 28 days. Infectious complications occurred in 30% of the probiotic group and 28% of the placebo group (relative risk 1.06, 95% CI 0.75-1.51). Mortality was higher with probiotics at 16% versus 6% for placebo (relative risk 2.53, 95% CI 1.22-5.25), alongside nine cases of bowel ischaemia.
Besselink MG, van Santvoort HC, Buskens E, et al. Lancet, 2008. PMID 18279948
2008 / Randomized controlled trial
Fifteen healthy subjects consumed cereal-based bread evening meals varying in GI and indigestible carbohydrates to assess effects on a subsequent standardized breakfast. Evening meals with barley kernel-based bread or white wheat bread (WWB) enriched with barley fiber and resistant starch improved glucose tolerance at breakfast compared with unsupplemented WWB (P < 0.05). Following barley-kernel bread, IL-6 was lower (P < 0.01) and adiponectin was higher (P < 0.05) compared with WWB. Glucose response at breakfast was inversely correlated with colonic fermentation (r = -0.25; P < 0.05) and GLP-1 (r = -0.26; P < 0.05), while breath hydrogen correlated positively with satiety (r = 0.27; P < 0.01) and inversely with gastric emptying rate (r = -0.23; P < 0.05).
Nilsson AC, Ostman EM, Holst JJ, et al. J Nutr, 2008. PMID 18356328
2008 / Comparative crossover trial
In 8 FD patients and 8 healthy controls, dyspeptic symptoms, appetite perceptions, plasma hormones, and antral area were evaluated on three separate days after high-carbohydrate, high-fat (500 kcal/400 g), or low-nutrient control (180 kcal/400 g) meals, followed by energy intake quantification 60 minutes later. In FD patients, nausea (P < 0.01) and pain (P = 0.05) were greater after the high-fat meal compared to high-carbohydrate and control meals and compared to healthy subjects. Fasting CCK and high-fat-stimulated CCK (P < 0.01) were higher, while fasting and postprandial PYY were lower (P < 0.001) in FD patients than controls. Fasting antral area was larger in FD (P < 0.05), but postprandial antral area, ghrelin levels, and subsequent energy intake did not differ between groups.
Pilichiewicz AN, Feltrin KL, Horowitz M, et al. Am J Gastroenterol, 2008. PMID 18775003
2008 / Randomized controlled trial
In a randomized trial, patients who had colorectal adenomas removed and confirmed clean colon at 1 year were assigned to 1.5 g green tea extract daily (n=71) or no supplementation (n=65) for 12 months. Among the 125 patients completing follow-up colonoscopy, the incidence of metachronous adenomas was 15% (9 of 60) in the green tea extract group versus 31% (20 of 65) in controls (relative risk, 0.49; 95% CI, 0.24-0.99; P < 0.05). Relapsed adenoma size was also significantly smaller in the supplemented group (P < 0.001), with no serious adverse events reported.
Shimizu M, Fukutomi Y, Ninomiya M, et al. Cancer Epidemiol Biomarkers Prev, 2008. PMID 18990744
2007 / Randomized crossover trial and preclinical study
In a randomized crossover trial of 10 healthy volunteers, indomethacin caused a threefold increase in gut permeability in the control arm, with lactulose:rhamnose ratios shifting from mean (SEM) 0.35 (0.035) to 0.88 (0.11) after 5 days (p<0.01). In contrast, no significant increase in gut permeability was seen when zinc carnosine was coadministered. In accompanying preclinical work, zinc carnosine stimulated epithelial cell migration and proliferation and reduced gastric and small-intestinal injury.
Mahmood A, FitzGerald AJ, Marchbank T, et al. Gut, 2007. PMID 16777920
2007 / Randomized, double-blind, placebo-controlled crossover trial
Sixty-four healthy adults consumed 45 g sucrose or 20, 35, and 50 g of erythritol or xylitol dissolved in water in random order with 7-day washout periods. Compared to 45 g sucrose, 50 g xylitol significantly increased reports of nausea (P<0.01), bloating (P<0.05), borborygmi (P<0.005), colic (P<0.05), watery feces (P<0.05), and total bowel movement frequency (P<0.01), while 35 g xylitol increased watery feces (P<0.05). Conversely, 50 g erythritol only significantly increased nausea (P<0.01) and borborygmi (P<0.05), with 20 g and 35 g causing no significant increase in GI symptoms. At all intake levels, xylitol produced significantly more watery feces than erythritol.
Storey D, Lee A, Bornet F, et al. Eur J Clin Nutr, 2007. PMID 16988647
2007 / Randomized double-blind placebo-controlled trial
Eight healthy volunteers consumed 300 GalU, 1200 GalU of alpha-galactosidase, or placebo alongside a test meal containing 420 g of cooked beans. Over an 8-hour period, 1200 GalU significantly lowered breath hydrogen excretion and flatulence severity. In addition, both the 300 and 1200 GalU doses significantly decreased overall gas-related symptom scores compared to placebo.
Di Stefano M, Miceli E, Gotti S, et al. Dig Dis Sci, 2007. PMID 17151807
2007 / Sequential dietary intervention trial
Nineteen healthy, obese volunteers were given three diets sequentially: a 3-day maintenance diet (399 g carbohydrate/day), followed by 4 weeks of high-protein/medium-carbohydrate (164 g/day), and 4 weeks of high-protein/low-carbohydrate (24 g/day). Total fecal short-chain fatty acids significantly fell from 114 mM to 74 mM and 56 mM (P < 0.001), with a disproportionate drop in butyrate from 18 mM to 9 mM and 4 mM (P < 0.001). Concurrently, the Roseburia spp. and Eubacterium rectale subgroup decreased from 11% to 8% and 3% (P < 0.001), and bifidobacteria dropped from 4% to 2.1% and 1.9% (P = 0.026).
Duncan SH, Belenguer A, Holtrop G, et al. Appl Environ Microbiol, 2007. PMID 17189447
2007 / Randomized crossover trial
In 15 patients with reflux symptoms, a catheter-free system monitored esophageal pH over 4 days across 4 dietary conditions: high-fat (50%) vs low-fat (25%), and high-calorie (1000 kcal) vs low-calorie (500 kcal). Esophageal acid exposure was higher during the high-calorie than the low-calorie diet (mean, 8.6% +/- 2.0% vs 5.2% +/- 1.4% time pH < 4/24 h; P < .01), with no difference between high-fat and low-fat diets (8.6% +/- 2.0% vs 8.2% +/- 1.6%; P = NS). Conversely, reflux symptom frequency was unaffected by calorie density (P = NS) but was significantly increased by the high-fat compared with the low-fat diet (median, 11 vs 6; P < .05). Meal consistency had no effect.
Fox M, Barr C, Nolan S, et al. Clin Gastroenterol Hepatol, 2007. PMID 17363334
2007 / Prospective double-blind placebo-controlled randomized trial
Fifty-seven patients with irritable bowel syndrome were randomly assigned to receive enteric-coated peppermint oil (two capsules twice daily) or placebo for 4 weeks, with symptoms assessed at baseline (T0), week 4 (T4), and 4 weeks post-therapy (T8). At T4, 75% of the peppermint oil group achieved a >50% reduction in baseline total IBS symptoms score compared with 38% in the placebo group (P<0.009). The total symptoms score dropped significantly in the peppermint oil group from 2.19+/-0.13 at T0 to 1.07+/-0.10 at T4 and 1.60+/-0.10 at T8 (P<0.01 vs T0), whereas no change occurred with placebo.
Cappello G, Spezzaferro M, Grossi L, et al. Dig Liver Dis, 2007. PMID 17420159